<DOC>
	<DOCNO>NCT00297804</DOCNO>
	<brief_summary>The clinical investigation international , prospective , multi-center , double-blind , randomized safety efficacy trial . The purpose study evaluate safety effectiveness TAXUS ( TM ) Stent System 1µg/mm2 ( load drug/stent surface area ) paclitaxel incorporate moderate rate-release formulation triblock copolymer carrier system patient high risk target lesion revascularisation restenosis .</brief_summary>
	<brief_title>A Randomized , Double-blind Study Assess Paclitaxel-eluting Stents Treatment Longer Lesions</brief_title>
	<detailed_description>The ultimate goal paclitaxel elute stent system prevent restenosis blunt initial response stent implant injury sustain arrest response vascular heal take place . The purpose TAXUS VI trial study safety efficacy TAXUS ( TM ) Stent control trial circumstance target patient high risk target lesion revascularisation restenosis . The study population include long lesion , small diameter vessel , multiple lesion vessel , allow use 2 randomize study stent . The clinical investigation evaluate safety effectiveness TAXUS ( TM ) Stent 1 µg/mm2 ( load drug/stent surface area ) paclitaxel incorporate moderate rate-release formulation triblock copolymer carrier system treatment de novo coronary artery lesion . Patients stratify site presence absence medically treat diabetes mellitus randomize receive either TAXUS ( TM ) Stent uncoated EXPRESS ( TM ) stent . The primary objective study show superior 9-month target vessel revascularization ( TVR ) rate TAXUS ( TM ) Stent compare uncoated Express ( TM ) control stent .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>General Inclusion Criteria 1 . Patient &gt; or= 18 year old 2 . Eligible percutaneous coronary intervention 3 . Documented stable angina pectoris unstable angina pectoris document ischemia document silent ischemia 4 . Acceptable candidate CABG 5 . Patient ( legal guardian ) understand study requirement treatment procedure provide write Informed Consent studyspecific test procedure perform 6 . Willing comply specify followup evaluation Angiographic Inclusion Criteria 1 . Target lesion locate within single native coronary vessel 2 . Target lesion randomize treatment study device may compose multiple lesion must completely coverable 2 study stent ( maximum allowable stent length 48 mm ) . 3 . Cumulative target lesion length &gt; or= 18 mm &lt; or= 40 mm ( visual estimate ) 4 . RVD &gt; or= 2.5 mm &lt; or= 3.75 mm ( visual estimate ) 5 . Target lesion diameter stenosis &gt; or=50 % ( visual estimate ) 6 . Target lesion de novo General 1 . Known sensitivity paclitaxel 2 . Any previous plan treatment antirestenotic drugcoated drugeluting coronary stent ( Note : previous plan treatment heparin phosphorylcholine coat stent acceptable , long procedure stent meet protocol define criterion stag procedure ) 3 . Previous plan treatment intravascular brachytherapy target vessel 4 . MI within 72 hour prior study procedure and/or CKMB &gt; 2x local laboratory 's upper limit normal ( refers measure value day study procedure ) 5 . Left ventricular ejection fraction &lt; 25 % 6 . Cerebrovascular Accident within past 6 month 7 . Acute chronic renal dysfunction ( creatinine &gt; 1.7 mg/dl &gt; 150 µmol/L ) 8 . Contraindication ASA , clopidogrel ticlopidine 9 . Leukopenia ( leukocyte count &lt; 3.5 x 109/liter ) 10 . Thrombocytopenia ( platelet count &lt; 100,000/mm3 ) 11 . Active peptic ulcer active gastrointestinal bleeding 12 . Known allergy stainless steel 13 . Any prior true anaphylactic reaction contrast agent 14 . Known anaphylactoid nonanaphylactic allergic reaction contrast agent adequately premedicated prior study procedure 15 . Patient currently take colchicine 16 . Patient currently , treat paclitaxel within 12 month study procedure 17 . Female childbearing potential positive pregnancy test within 7 day study procedure , lactating , intend become pregnant study 18 . Life expectancy le 24 month due medical condition 19 . Comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study 20 . Currently participate another investigational drug device study complete primary endpoint clinically interfere endpoint study Angiographic Exclusion Criteria 1 . Left main coronary artery disease ( stenosis &gt; 50 % ) , whether protect unprotected 2 . Target lesion ostial location ( within 3.0 mm vessel origin ) 3 . Target lesion ( ) and/or target vessel proximal target lesion ( ) moderately severely calcified visual estimation 4 . Target lesion locate within distal &gt; 60°bend vessel 5 . Target lesion involve bifurcation diseased ( &gt; 50 % stenotic ) branch vessel &gt; 2.0 mm diameter 6 . Target lesion totally occluded Thrombolysis MI ( TIMI flow &lt; or= 1 ) 7 . Angiographic presence probable definite thrombus 8 . Target vessel pretreated unapproved device , directional rotational coronary atherectomy , laser , cut balloon transluminal extraction catheter immediately prior stent placement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
	<keyword>Stent Implant</keyword>
	<keyword>Drug-coated Stent</keyword>
</DOC>